With the advent of Immune Checkpoint Inhibitors (ICIs), specially programmed death-1 (PD-1) inhibitors (Pembrolizumab, Nivolumab), and programmed death-ligand 1 (PD-L1) inhibitors (Durvalumab, Avelumab, and atezolizumab), the therapeutic landscape of immunotherapy has been changed in NSCLC.[9] PD-1/PD-L1 inhibitors have revealed a remarkable impact in overall survival relative to chemotherapy in NSCLC.[10,11]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.